Dry Eye Disease Pipeline Insight Report: 50+ Companies | DelveInsight

DelveInsight's, "Dry Eye Disease Pipeline Insight, 2022," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Dry Eye Disease Pipeline Insight Report

• DelveInsight's Dry Eye Disease pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline therapies.
• The leading Dry Eye Disease Companies are working such as TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others.
• Promising Dry Eye Disease Pipeline Therapies such as Reproxalap, Timbetasin, Visomitin, and others.
• The Dry Eye Disease Companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The Dry Eye Disease pipeline therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.


Recent Breakthroughs of Dry Eye Disease Treatment Landscape

• In a Phase II b clinical trial, Aldeyra's lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.
• RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.
• Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.


Request a sample and discover the recent advances in Dry Eye Disease Medication and Dry Eye Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Eye Disease Overview

Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality. Dry eyes can develop for many reasons, including: Age, gender, medications, medical conditions (people with rheumatoid arthritis, diabetes, and thyroid problems are more likely to have symptoms of dry eyes. Also, problems with inflammation of the eyelids (blepharitis), inflammation of the surfaces of the eye, or the inward or outward turning of eyelids can cause dry eyes to develop) and other factors such as long-term use of contact lenses can be a factor in the development of dry eyes. Refractive eye surgeries, such as LASIK, can decrease tear production and contribute to dry eyes.

Dry Eye Disease Emerging Drugs

• Reproxalap: Aldeyra Therapeutics
• Timbetasin: RegeneRx Biopharmaceuticals
• Visomitin: Mitotech

Dry Eye Disease Pipeline Therapeutic Assessment

There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals.



DelveInsight's Dry Eye Disease Pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Dry Eye Disease pipeline therapies and Dry Eye Disease Clinical Trials @ https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr


Scope of the Dry Eye Disease Pipeline Report

• Coverage- Global
• Dry Eye Disease Pipeline Assessment by Product Type
• Dry Eye Disease Pipeline Assessment by Stage and Product Type
• Dry Eye Disease Pipeline Assessment by Route of Administration
• Dry Eye Disease Pipeline Assessment by Stage and Route of Administration
• Dry Eye Disease Pipeline Assessment by Molecule Type
• Dry Eye Disease Pipeline Assessment by Stage and Molecule Type
• Dry Eye Disease Companies- TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others.
• Dry Eye Disease Pipeline Therapies- Reproxalap, Timbetasin, Visomitin, and others

Read more about the Dry Eye Disease Emerging Drugs, Companies, Assessments @ https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Dry Eye Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Eye Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name: Company Name
9. Last Stage Products (Phase III)
10. Timbetasin: RegeneRx Biopharmaceuticals
11. Mid Stage Products (Phase II)
12. Drug name: Company name
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Dry Eye Disease Key Companies
17. Dry Eye Disease Key Products
18. Dry Eye Disease - Unmet Needs
19. Dry Eye Disease - Market Drivers and Barriers
20. Dry Eye Disease - Future Perspectives and Conclusion
21. Dry Eye Disease Analyst Views
22. Dry Eye Disease Key Companies
23. Appendix


Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dry Eye Disease drugs?
• How many Dry Eye Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dry Eye Disease and their status?
• What are the key designations that have been granted to the emerging drugs?


Got Queries? Dry Eye Disease Market Drivers and Barriers @ https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.